We hypothesize that circulating biomarkers of subclinical inflammation predict the deterioration of insulin sensitivity and beta-cell function and the progression of micro- and macrovascular comorbidities in patients with newly diagnosed DM. The gene discussed is INS; the disease is diabetes mellitus.